Risk of infections associated with biological treatment in inflammatory bowel disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of infections associated with biological treatment in inflammatory bowel disease
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 20, Issue 43, Pages 16014
Publisher
Baishideng Publishing Group Inc.
Online
2016-03-12
DOI
10.3748/wjg.v20.i43.16014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
- (2014) J.F. Rahier et al. Journal of Crohns & Colitis
- Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti-Tumor Necrosis Factor-α Therapy
- (2014) In Kyung Yoo et al. YONSEI MEDICAL JOURNAL
- Association Between the Initiation of Anti–Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster
- (2013) Kevin L. Winthrop et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Pooled Analysis of Infections, Malignancy and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Infliximab for Crohn’s Disease: The First 500 Patients Followed Up Through 2009
- (2012) Jennifer L. Seminerio et al. DIGESTIVE DISEASES AND SCIENCES
- Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening
- (2012) Aranzazu Jauregui-Amezaga et al. Journal of Crohns & Colitis
- Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis
- (2011) Jeffrey Hyams et al. Clinical Gastroenterology and Hepatology
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
- (2011) Carlos G. Grijalva et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
- (2010) I. Solovic et al. EUROPEAN RESPIRATORY JOURNAL
- QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States
- (2010) Bashar J. Qumseya et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
- (2010) J. B. Galloway et al. RHEUMATOLOGY
- Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
- (2009) Anja Strangfeld JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparison of Interferon-Gamma Release AssayVersusTuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease
- (2008) Alain M. Schoepfer et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
- (2008) H Fidder et al. GUT
- Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease
- (2008) Jeffrey S. Hyams et al. INFLAMMATORY BOWEL DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started